

PTO/SB/08A

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

| | |
|----------------------|-------------------|
| Application Number | 09/997,974 |
| Filing Date | November 30, 2001 |
| First Named Inventor | Salvamini |
| Confirmation No. | 5898 |

Sheet P/E 1

of 5

Attorney Docket No.

MPEP 609-3

RECEIVED

APR 11 2002
PATENT & TRADEMARK OFFICE

RECEIVED

APR 16 2002

U.S. PATENT DOCUMENTS

TECH CENTER 1600/2900

| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
|--------------------|-----------------------|----------------------|--------------------------------------|---|---|
| | | Number | Kind Code ² (if known) | | |
| KCF | 1 | 4,877,561 | | Iga et al. | 10-31-1989 |
| KCF | 2 | 4,999,347 | | Sorenson | 03-12-1991 |
| KCF | 3 | 5,541,174 | | Sorenson | 07-30-1996 |
| KCF | 4 | 5,637,578 | | Riley et al. | 06-10-1997 |
| KCF | 5 | 5,874,421 | | Riley et al. | 06-10-1997 |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | T ⁶ |
|--------------------|-----------------------|-------------------------|---------------------|--------------------------------------|---|---|----------------|
| | | Office | Number ⁴ | Kind Code ² (if known) | | | |
| KCF | 6 | CN | 1088086 | A | Univ Xibei (Uyxi-N) | 12-1992 | X |
| KCF | 7 | EP | 0 524 161 | A1 | Monsanto Company | 01-20-1993 | |
| KCF | 8 | WO | 94/15925 | A1 | Monsanto Company | 07-21-1994 | |
| KCF | 9 | WO | 96/39396 | A1 | Monsanto Company | 12-12-1996 | |
| KCF | 10 | WO | 97/33877 | A1 | Monsanto Company | 09-18-1997 | |

RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

AUG 14 2002

| | | | | |
|--------------------|--------------------|-----------------|---------|-----------------------|
| Examiner Signature | <i>R. R. Donde</i> | Date Considered | 12-5-02 | TECH CENTER 1600/2900 |
|--------------------|--------------------|-----------------|---------|-----------------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

O I P E
PATENT & TRADEMARK OFFICE
APR 11 2002

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

RECEIVED

(use as many sheets as necessary)

APR 18 2002

| | | Complete if Known | |
|-------|---|--------------------------|-------------------|
| | | Application Number | 09/997,974 |
| | | Filing Date | November 30, 2001 |
| | | First Named Inventor | Salvamini |
| | | Confirmation No. | 5898 |
| Sheet | 2 | of | GROUP 3600 |
| | | Attorney Docket No. | MPI 8313.3 |

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, and/or country where published. | <i>TECH CENTER 1600/2900</i> |
|--------------------|-----------------------|--|------------------------------|
| <i>KCF</i> | 11 | The Merck Index, Twelfth Edition, S. Budavari, editor. Merck & Co., Inc., Whitehouse Station, NJ, 1996 pages 1540-41, monograph 9177. | |
| <i>KCF</i> | 12 | BANNISTER, et al., "Aspects of the Structure, Function, and Applications of Superoxide Dismutase." Crit. Rev. Biochem., 1987, Vol. 22(2), 111-180 | |
| <i>KCF</i> | 13 | BAUEROVA, et al., "Role of Reactive Oxygen and Nitrogen Species in Etiopathogenesis of Rheumatoid Arthritis, Gen. Physiol. Biophys., Vol. 18, 15-20, 1999 | |
| <i>KCF</i> | 14 | COMHAIR et al., "Rapid Loss of Superoxide Dismutase Activity During Antigen-Induced Asthmatic Responses." Departments of Pulmonary and Critical Care Medicine, and Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, <i>NO DATE AVAILABLE</i> | |
| <i>KCF</i> | 15 | CUZZOCREA, et al., "Beneficial Effects on Tempol, a Membrane-Permeable Radical Scavenger, in a Rodent Model of Collagen-Induced Arthritis." Arthritis & Rheumatism, 2000, Vol. 43, 320-328 | |
| <i>KCF</i> | 16 | DEL VILLANO, et al., "Elevated Superoxide Dismutase in Black Alcoholics," 1980, (Science, Vol. 207 pp. 991-993 | |
| <i>KCF</i> | 17 | DE RAEVE et al. "Decreased Cu,Zn-SOD activity in asthmatic airway epithelium: corection by inhaled corticosteroid in vivo." 1997, The american Physiological Society, pp. L148-L154. | |
| <i>KCF</i> | 18 | ELMER, et al., "Transgenic Superoxide Dismutase Mice Differ in Opioid-Induced Analgesia," 1995, European Journal of Pharmacology, Vol. 283, pp. 227-232. | |
| <i>KCF</i> | 19 | FERRAUDI, "Photochemistry of High-Spin Iron(III) Complexes of the Macroyclic Ligands [15]pydineN ₅ and [15]pyaneN ₅ . An Investigation of the Charge-Transer Processes." Inorg. Chem., 1980, pp. 438-444, Vol. 19. | |
| <i>KCF</i> | 20 | GOLDSTEIN, et al., "Exogenous Gaseous Superoxide Potentiates the Antinociceptive Effect of Opioid Analgesic Agents," 1996, Inflamm Res., Vol. 45, pp. 473-478. | |
| <i>KCF</i> | 21 | GRIFFITHS, M.M., et al., "Immunogenetic Control of Experimental Type II Collagen-Induced Arthritis, Arthritis Rheum, 1981, Vol. 2, 781-789 | |
| <i>KCF</i> | 22 | HARDY, et al., "Superoxide Dismutase Mimetics Inhibit Neutrophil-mediated Human Aortic Endothelial Cell Injury <i>in Vitro</i> , The Journal of Biological Chemistry, 1994, Vol. 269, No. 28, 18535-18540 | |

| | | | |
|--------------------|-----------------|-----------------|------------------------------|
| Examiner Signature | <i>RR Donda</i> | Date Considered | RECEIVED |
| | | 12-5-02 | <i>TECH CENTER 1600/2900</i> |
| AUG 14 2002 | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

O I P F
APR 11 2002
P A T E N T & T R A D E M A R K O F F I C EINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

RECEIVED

Complete if Known

Application Number 09/997,974

Filing Date November 30, 2001

First Named Inventor Salvagno

Confirmation No. 5898

Sheet

3

of

APR 18 2002

Attorney Docket No.

RECEIVED

APR 16 2002

MPI 8313.3

GROUP 3600

TECH CENTER 1600/2900

| | | |
|-----|----|--|
| KCF | 23 | HUBER et al., "Superoxide Dismutase Pharmacology and Orgotein Efficacy: New Perspectives." 1980, Dev. Biochem. Vol. 11B, pp. 395-407. |
| KCF | 24 | KATAOKA, et al., "Hydroxyl Radical Scavenging Activity of Nonsteroidal Anti-Inflammatory Drugs, "Free Rad. Res., 1997, Vol 27(4) 419-427 |
| KCF | 25 | KOHÚT, et al., "Effect of Allopurinol and Superoxide Dismutase on Indomethacin-Induced Gastric Lesions in the Rat," 1993, Physiol. Res., Vol. 42. pp. 273-276. |
| KCF | 26 | JOYAVE, et al., "Alteration of Chemically Induced Hepatotoxicity by Copper (II) (3,5-Diisopropylsalicylate) ₂ ," 1985, Biochemical Pharmacology, Vol. 34, No. 21, pp. 3915-3919. |
| KCF | 27 | LENGFELDER, et al., "Superoxide Dismutation by Low Molecular Weight Cu-Complexes," 1981, Bull Europ Physiopath. Resp., Vol. 17 pp. 73-80. |
| KCF | 28 | LI, et al., "Synthesis and Pharmacological Activities of 1,1-Dialkyl-4 (3-Bromopropionyl) Piperazinium Bromides," 1996, Acta Pharmacologica Sinica, Vol. 31, pp. 757-760. |
| KCF | 29 | LIN, et al., "Use of Superoxide Dismutase (SOD) in Patients with Temporomandibular Joint Dysfunction - a Preliminary Study," 1994, Int. J. Oral Maxillofac. Surg., Vol. 23, pp. 428-429 |
| KCF | 30 | LLESUY et al., "Oxidative Stress in Muscle and Liver of Rats with Septic Syndrome" Free Radical Biology & Medicine, Vol. 16, No. 4, 445-451, 1994 |
| KCF | 31 | MACARTHUR, et al., "Inactivation of Catecholamines by Superoxide Gives New Insights on the Pathogenesis of Septic Shock." PNAS, 2000, Vol 97(17), 9753-9758 |
| KCF | 32 | MAO, et al., "Mechanisms of hyperalgesia and Morphine tolerance: a current view of their possible interactions," 1995, Pain, Vol. 62, pp. 359-274. |
| KCF | 33 | MATTEY, et al., "Influence of Polymorphism in the Manganese Superoxide Dismutase Locus on Disease Outcome in Rheumatoid Arthritis" Arthritis & Rheumatism, 2000, 859-864, Vol. 43. |
| KCF | 34 | McCord, "Superoxide Dismutase: Rationale for Use in Reperfusion Injury and Inflammation." Journal of Free Radicals in Biology & Medicine, 1986, Vol 2, 307-310 |
| KCF | 35 | MERTENS, et al., "Study of eosinophil-endothelial adhesion, production of oxygen radicals and release of eosinophil cationic protein by peripheral blood eosinophils of patients with rheumatoid arthritis" Clinical and Experimental Allergy, Vol. 23 868-873. (1993) |
| KCF | 36 | "Modified Superoxide Dismutase as Inflammation Inhibitor and Others," 1989, (Chemical Abstracts) Vol. 111, No. 15) p.353. |

RECEIVED

Examiner
Signature

R. Ondre

Date
Considered

12-5-02

AUG 14 2002


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

TECH CENTER 1600/2900

PTO/SB/08A


INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

RECEIVED

| | | | | | |
|-------|---|----|-------------|---------------------|-------------------|
| Sheet | 4 | of | APR 18 2002 | Attorney Docket No. | MPI 831331 6 2002 |
|-------|---|----|-------------|---------------------|-------------------|

GROUP 3600**TECH CENTER 1600/2900**

| | | |
|-----|----|--|
| KRF | 37 | OKUYAMA, et al., "Copper Complexes of Non-steroidal Antiinflammatory agents: Analgesic Activity and Possible Opioid Receptor Activation," 1987, Agents and Actions, Vol. 21, 1/2, pp. 130-144. |
| KRF | 38 | ORVISKY, et al., "High-Molecular-Weight Hyaluronan--a Valuable tool in Testing the Antioxidative Activity of Amphiphilic Drugs Stobadine and Vinpocetine." Journal of Pharmaceutical and Biomedical Analysis, 1997, Vol 16, 419-424 |
| KRF | 39 | PARFITT, et al., "Bone Histomorphometry: Standardization of Nomenclature, Symbols, and Units." Journal of Bone and Mineral Research, 1987, Vol 2, 595-610 |
| KRF | 40 | PETKAU, "Scientific Basis for the Clinical Use of Superoxide Dismutase." Cancer Treatment Reviews, 1986, Vol 13, 17-44 |
| KRF | 41 | RAKOWSKI et al., "Synthesis and Characterization of Transition Metal Complexes Containing a Pentadentate Macroyclic Ligand." Inorganic Chemistry, 1975, pp. 1194-1200, Vol. 14, No. 5. |
| KRF | 42 | RILEY et al., "Rational Design of Synthetic Enzymes and Their Potential Utility as Human Pharmaceuticals" CatTech, I, 41, 1997 |
| KRF | 43 | RILEY et al., "Stopped-Flow Kinetic Analysis for Monitoring Superoxide Decay in Aqueous Systems, Analytical Biochemistry, Vol., 196, 344-349, 1991 |
| KRF | 44 | RILEY et al., "Synthesis, Characterization, and Stability of Manganese (II) C-Substituted 1,4,7,10,13-Pentaazacyclopentadecane Complexes Exhibiting Superoxide Dismutase Activity." Inorg. Chem, 1996, pp. 5213-5231, Vol. 35. |
| KRF | 45 | SALVEMINI et al., "A Nonpeptidyl Mimic of Superoxide Dismutase with Therapeutic Activity in Rats." Science, 1999, pp. 304-306, Vol. 286. |
| KRF | 46 | SHUFF, et al., "Stable Superoxide Dismutase (SOD)-Mimetic Ternary Human Serum Albumin-Cu(II)(3,5-Diisopropylsalicylate) ₄ Complexes in Tissue Distribution of the Binary Complex," 1992, Biochemical Pharmacology, Vol. 43, No. 7, pp. 1601-1612. |
| KRF | 47 | M. TAL, "A Novel Antioxidant Alleviates heat Hyperalgesia in Rats with an Experimental Painful Peripheral Neuropathy," 1996, NeuroReport, Vol. 7, pp. 1382-1384 |
| KRF | 48 | TAWARA, T., et al., "Effects of Recombinant Human IL-1 b on Production of Prostaglandin E2, Leukotriene B4, NAG, and Superoxide by Human Synovial Cells and Chondrocytes" Inflammation, 1991, Vol. 15, No. 2, 145-157 |
| KRF | 49 | TAYLOR, et al., "Oxidative Metabolism in Sepsis and Sepsis Syndrome" Journal of Critical Care, 1995, Vol. 10, No. 3, 122-135 |

RECEIVED

| | | | | |
|--------------------|----------------------|-----------------|---------|-------------|
| Examiner Signature | <i>R. R. Dondero</i> | Date Considered | 12-5-02 | AUG 14 2002 |
|--------------------|----------------------|-----------------|---------|-------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TECH CENTER 1600/2900

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



| | | | | | |
|--|---|----|---|---|---------------------------|
| PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 09/997,974 |
| | | | | Filing Date | November 30, 2001 |
| | | | | First Named Inventor | RECEIVED |
| | | | | Confirmation No. | 5898 |
| | | | | Attorney Docket No. | APR 16 2002 MPI 8313.3 |
| Sheet | 5 | of | 5 | GROUP 3600 TECH CENTER 1600/2900 | |

| | | |
|------------|----|--|
| <i>KKF</i> | 50 | TIKU, et al., "Evidence Linking Chondrocyte Lipid Peroxidation to Cartilage Matrix Protein Degradation" J. Biol. Chem., 2000, 20069-20076, Vol. 275. |
| <i>KKF</i> | 51 | VARSANO, et al., "Superoxide Dismutase Activity in Morphine- and Meperidine- Addicted Mice and Their Response to Paraquat Poisoning," 1992, (FEBS) pp. S54-S59. |
| <i>KKF</i> | 52 | WATSON, et al., "Human HLA-DR β Gene Hypervariable Region Homology in the BioBreeding BB Rat: Selection of the Diabetic-resistant Subline as a Rheumatoid Arthritis Research Tool to Characterize the Immunopathologic Response to Human Type II Collagen, J. Exp. Med., 1990, Vol. 172, 1331-1339 |
| <i>KKF</i> | 53 | WEISS, R.H., et al., "Manganese-Based Superoxide Dismutase Mimics: Design, Discovery and Pharmacologic Efficacies" The Oxygen Paradox, Davies, K.J.A., and Ursini, F., Eds. pp. 641-651, CLEUP University Press, Padova, Italy |
| <i>KKF</i> | 54 | WEISS, R. H., et al., "Manganese-based Superoxide Dismutase Mimetics Inhibit Neutrophil Infiltration in Vivo," The Journal of Biological Chemistry, Vol. 271, No. 42, 26149-26156, 1996 |
| <i>KKF</i> | 55 | WEISS, R. H., et al., "Manganese (II) - Based Superoxide Dismutase Mimetics: Rational Drug Design of Artificial Enzymes" Drugs of the Future, 21, 383-389, 1996 |
| <i>KKF</i> | 56 | WEISS, R. H., et al., "Keystone Symposia on the Molecular Basis of Oxidative Damage by Leukocytes." J. Cell. Biochem., 1991, Suppl. 15C, 216 |
| <i>KKF</i> | 57 | WEISS, R.H., et al., "Therapeutic Aspects of Manganese(II)-based Superoxide Dismutase Mimics." Inorganic Chemistry in Medicine, (Farrell, N., Ed.), Royal Society of Chemistry |
| <i>KKF</i> | 58 | WEISS, R.H., et al., "Evaluation of Activity of Putative Superoxide Dismutase Mimics." Journal of Biological Chemistry, 1993, Vol. 268(31), 23049-23054 |

RECEIVED

AUG 14 2002

TECH CENTER 1600/2900

| | | | |
|--------------------|--------------------|-----------------|---------|
| Examiner Signature | <i>R. R. Donde</i> | Date Considered | 12-5-02 |
|--------------------|--------------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.